ADALAT Drug Patent Profile

Which patents cover Adalat, and what generic alternatives are available?

Adalat is a drug marketed by Bayer Pharms and Norwich and is included in two NDAs.

The generic ingredient in ADALAT is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the nifedipine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adalat

A generic version of ADALAT was approved as nifedipine by ACTAVIS ELIZABETH on January 8^th, 1991.

Summary for ADALAT

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	129
Clinical Trials:	29
Patent Applications:	4,347
Drug Prices:	Drug price information for ADALAT
DailyMed Link:	ADALAT at DailyMed

See drug prices for ADALAT

Recent Clinical Trials for ADALAT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cao Yu	Phase 1
Jing Liu	Phase 4
Columbia University	Phase 4

See all ADALAT clinical trials

US Patents and Regulatory Information for ADALAT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Pharms	ADALAT	nifedipine	CAPSULE;ORAL	019478-001	Nov 27, 1985		DISCN	No	No
Norwich	ADALAT CC	nifedipine	TABLET, EXTENDED RELEASE;ORAL	020198-002	Apr 21, 1993		DISCN	Yes	No
Bayer Pharms	ADALAT	nifedipine	CAPSULE;ORAL	019478-002	Sep 17, 1986		DISCN	No	No
Norwich	ADALAT CC	nifedipine	TABLET, EXTENDED RELEASE;ORAL	020198-001	Apr 21, 1993		DISCN	Yes	No
Norwich	ADALAT CC	nifedipine	TABLET, EXTENDED RELEASE;ORAL	020198-003	Apr 21, 1993		DISCN	Yes	No

Expired US Patents for ADALAT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Pharms	ADALAT	nifedipine	CAPSULE;ORAL	019478-001	Nov 27, 1985
Bayer Pharms	ADALAT	nifedipine	CAPSULE;ORAL	019478-002	Sep 17, 1986
Bayer Pharms	ADALAT	nifedipine	CAPSULE;ORAL	019478-002	Sep 17, 1986
Bayer Pharms	ADALAT	nifedipine	CAPSULE;ORAL	019478-001	Nov 27, 1985

International Patents for ADALAT

See the table below for patents covering ADALAT around the world.

Country	Patent Number	Title	Estimated Expiration
Bulgaria	27728	METOD ZA POLUCHAVANE NA KORONARNO SREDSTVO (METHOD FOR OBTAINING OF CORONAL MEANS)
South Africa	7205808
Czechoslovakia	199202	METHOD OF PRODUCING GELATINE CAPSULES TO BE BITTEN UP
Finland	53922
Austria	A723072
France	2150848
South Korea	780000433

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: ADALAT

Last updated: July 29, 2025

Introduction

ADALAT, known generically as nifedipine, is a calcium channel blocker primarily prescribed for hypertension and angina pectoris. Since its debut, ADALAT has established itself as a cornerstone therapy within cardiovascular management, with its market trajectory influenced by evolving healthcare landscapes, technological advancements, competitive dynamics, and regulatory policies. This analysis offers a comprehensive overview of the current market dynamics and financial trajectory of ADALAT, emphasizing key drivers, challenges, and future prospects critical for stakeholders.

---

Market Overview

ADALAT's global presence is underpinned by a substantial demand for antihypertensive agents. As per Grand View Research [1], the global antihypertensive drug market was valued at approximately USD 16.7 billion in 2021, with calcium channel blockers (CCBs) representing a significant segment. ADALAT, as a branded and generic formulation, occupies a prominent niche within this segment, driven by its proven efficacy and longstanding clinical use.

North America remains a dominant market owing to high hypertension prevalence, reimbursement infrastructure, and a healthcare ecosystem receptive to branded medications. Europe mirrors this trend with a mature market adopting both generics and branded drugs, while emerging markets such as Asia-Pacific demonstrate rapid growth owing to expanding healthcare access and increasing cardiovascular disease (CVD) burdens.

---

Market Dynamics Influencing ADALAT

1. Epidemiological Factors and Demographics

The escalating prevalence of hypertension globally, forecasted to impact 1.28 billion adults by 2025 [2], fuels demand for effective antihypertensive therapies, including ADALAT. Aging populations, particularly in developed economies, further augment this trend, amplifying the market size for calcium channel blockers. Growing awareness and early diagnosis bolster prescription volumes.

2. Competitive Landscape and Generic Penetration

ADALAT faces intense competition from other CCBs, both branded and generic. Notably, the advent of generic nifedipine formulations has intensified price competition, pressuring margins for branded versions. Industry dynamics reveal a trend towards biosimilar and alternative therapy preferences, compelling pharmaceutical companies to innovate in formulation or delivery methods.

3. Formulation Innovations and Extended-Release (ER) Versions

The development of sustained-release formulations of nifedipine, such as ADALAT CC, has expanded the therapeutic utility, offering improved compliance and better blood pressure control. The adoption of ER formulations correlates with increased market penetration and customer loyalty, influencing financial trajectories positively.

4. Regulatory Environment and Patent Expiry

Patent expirations significantly affect ADALAT’s revenue streams. While the original patent expiry led to the proliferation of generics, ongoing regulatory requirements, such as bioequivalence standards and approvals, pose barriers and opportunities. Companies investing in formulation patents or new delivery systems can sustain a competitive advantage.

5. Market Access and Reimbursement Policies

Coverage decisions by payers influence prescription rates. Favorable reimbursement policies for branded formulations in high-income countries maintain premium pricing structures. Conversely, cost containment measures and strict formulary restrictions in certain regions dampen growth prospects.

6. Technological Advancements and Digital Pharmaceutics

Emerging digital health initiatives, such as telemedicine and remote monitoring, foster increased adherence to antihypertensive regimens, indirectly stimulating ADALAT demand. Innovations in drug delivery mechanisms may further enhance efficacy and patient compliance.

---

Financial Trajectory and Revenue Projections

Current Revenue Landscape

Leading pharmaceutical firms with market rights, such as Bayer and Pfizer, derive significant revenue from ADALAT formulations. The global nifedipine market contributed an estimated USD 0.5 billion in 2021, with branded formulations accounting for approximately 30-40% of this figure, subject to regional variations [3].

Impact of Patent Expiry and Generics

Patent expiry, typically observed within 10-15 years from the launch, has historically resulted in a revenue decline for branded ADALAT. For instance, Bayer's original patent expired in numerous jurisdictions around 1999, leading to a surge in generic nifedipine availability. As a result, revenues from Bayer’s branded ADALAT have declined by an estimated 60% since patent expiration, replaced largely by generic sales.

Forecasting Future Revenue Streams

According to market analysts, the global antihypertensive drug market, including ADALAT, is poised to grow at a CAGR of approximately 3.5% through 2030 [4]. This growth will be driven primarily by emerging markets, aging demographics, and formulation advancements. However, if proprietary formulations or combination therapies are developed, the revenue trajectory can experience localized upticks despite generic competition.

Factors Supporting Revenue Stability

• Incremental innovations, such as sustained-release or controlled-dose formulations.
• Strategic alliances and licensing, extending market access.
• Entry into combination therapy markets, appealing to patients requiring polypharmacy.

Factors Limiting Future Growth

• Expiry of key patents, enabling broader generic penetration.
• Price erosion due to generic competition.
• Strict regulatory environments limiting new formulation approvals.

---

Emerging Market Opportunities and Challenges

Opportunities

Expanding healthcare infrastructure in Asia-Pacific, Latin America, and Africa offers a lucrative avenue for increased ADALAT procurement. Governments' emphasis on controlling CVD prevalence through accessible medications incentivizes local manufacturing and price optimization strategies.

Challenges

Pricing pressures, regulatory hurdles, and the need for clinical trial data for new formulations complicate market entry and expansion. Additionally, generic manufacturers can replicate formulations swiftly post-patent expiry, intensifying price competition.

---

Strategic Considerations for Stakeholders

• Innovation Focus: Investing in extended-release or combination formulations to differentiate branded offerings.
• Market Expansion: Targeting underpenetrated emerging markets with tailored pricing and educational campaigns.
• Regulatory Engagement: Navigating complex approval pathways efficiently to introduce new formulations.
• Cost Management: Optimizing manufacturing processes to maintain margins amidst pricing pressures.

---

Key Takeaways

• Epidemiology is a key growth driver for ADALAT, with global hypertension burdens fueling demand.
• The patent landscape significantly influences revenue, with generic competition constraining profit margins for branded versions.
• Formulation innovation, particularly extended-release variants, offers opportunities to sustain revenue streams and improve patient adherence.
• Emerging markets present substantial growth prospects, driven by increasing healthcare access, but pose challenges related to pricing, regulation, and local manufacturing.
• Strategic positioning, including diversification into combination therapies and digital health integration, is vital for long-term market viability.

---

Conclusion

ADALAT's market dynamics exemplify the complex interplay of epidemiological trends, regulatory evolution, competitive forces, and technological developments. While patent expiries and generic proliferation temper growth prospects, innovation-driven differentiation and market diversification remain pivotal. The financial trajectory hinges on strategic alignment with healthcare priorities, regional market conditions, and technological advancements. Stakeholders adopting agile, innovation-centric approaches can capitalize on the expanding global demand for effective antihypertensive therapies.

---

FAQs

Q1: How does patent expiry impact the revenue of ADALAT?
A1: Patent expiry allows generic manufacturers to enter the market, leading to significant price erosion for the branded drug and a decline in revenue for original patent holders.

Q2: What role do extended-release formulations play in ADALAT’s market penetration?
A2: Extended-release formulations improve patient adherence, offer better blood pressure control, and provide a competitive edge, thereby supporting sustained or increased market share.

Q3: Are there significant opportunities for ADALAT in emerging markets?
A3: Yes, expanding healthcare infrastructure and rising CVD prevalence make emerging markets promising, provided pricing strategies and regulatory pathways are effectively managed.

Q4: How is technological innovation influencing ADALAT’s market trajectory?
A4: Innovations such as digital adherence solutions and new delivery systems enhance therapeutic efficacy and patient compliance, potentially boosting demand.

Q5: What strategies can pharmaceutical companies adopt to maintain profitability with ADALAT?
A5: Companies should focus on formulation innovation, strategic geographic expansion, licensing, and integrating digital health tools to differentiate and sustain revenue streams.

---

References

[1] Grand View Research. "Antihypertensive Drugs Market Size & Trends." 2022.
[2] World Health Organization. "Global Brief on Hypertension." 2019.
[3] MarketWatch. "Global Nifedipine Market Analysis." 2022.
[4] MarketsandMarkets. "Antihypertensive Drugs Market Forecast." 2022.